schliessen

Filtern

 

Bibliotheken

Cover Image

Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial

Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing therapies will help achieve blood pressure (BP) goals in more resistant hypertension patients. In the current trial, 849 patients with resistant hypertension receiving ≥3... Full description

Journal Title: Hypertension (Dallas Tex. 1979), 2010-11, Vol.56 (5), p.824-830
Main Author: Bakris, George L
Other Authors: Lindholm, Lars H , Black, Henry R , Krum, Henry , Linas, Stuart , Linseman, Jennifer V , Arterburn, Sarah , Sager, Philip , Weber, Michael
Format: Electronic Article Electronic Article
Language: English
Subjects:
Aged
Antihypertensive Agents - therapeutic use
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood and lymphatic vessels
Blood Pressure - drug effects
Blood Pressure Monitoring, Ambulatory
Cardiac and Cardiovascular Systems
Cardiology. Vascular system
Clinical manifestations. Epidemiology. Investigative techniques. Etiology
Clinical Medicine
endothelin
endothelin antagonist
Endothelin Receptor Antagonists
Female
Guanfacine - therapeutic use
Humans
hypertension
Hypertension - drug therapy
Intention to Treat Analysis
Kardiologi
Klinisk medicin
Male
Medical and Health Sciences
Medical sciences
Medicin och hälsovetenskap
Middle Aged
Phenylpropionates - therapeutic use
Pyrimidines - therapeutic use
resistant hypertension
Treatment Outcome
Publisher: Hagerstown, MD: American Heart Association, Inc
ID: ISSN: 0194-911X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_DiVA_org_umu_41553
title: Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial
format: Article
creator:
  • Bakris, George L
  • Lindholm, Lars H
  • Black, Henry R
  • Krum, Henry
  • Linas, Stuart
  • Linseman, Jennifer V
  • Arterburn, Sarah
  • Sager, Philip
  • Weber, Michael
subjects:
  • Aged
  • Antihypertensive Agents - therapeutic use
  • Arterial hypertension. Arterial hypotension
  • Biological and medical sciences
  • Blood and lymphatic vessels
  • Blood Pressure - drug effects
  • Blood Pressure Monitoring, Ambulatory
  • Cardiac and Cardiovascular Systems
  • Cardiology. Vascular system
  • Clinical manifestations. Epidemiology. Investigative techniques. Etiology
  • Clinical Medicine
  • endothelin
  • endothelin antagonist
  • Endothelin Receptor Antagonists
  • Female
  • Guanfacine - therapeutic use
  • Humans
  • hypertension
  • Hypertension - drug therapy
  • Intention to Treat Analysis
  • Kardiologi
  • Klinisk medicin
  • Male
  • Medical and Health Sciences
  • Medical sciences
  • Medicin och hälsovetenskap
  • Middle Aged
  • Phenylpropionates - therapeutic use
  • Pyrimidines - therapeutic use
  • resistant hypertension
  • Treatment Outcome
ispartof: Hypertension (Dallas, Tex. 1979), 2010-11, Vol.56 (5), p.824-830
description: Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing therapies will help achieve blood pressure (BP) goals in more resistant hypertension patients. In the current trial, 849 patients with resistant hypertension receiving ≥3 antihypertensive drugs, including a diuretic, at optimized doses were randomized to the selective endothelin A receptor antagonist darusentan, placebo, or the central α-2 agonist guanfacine. The coprimary end points of the study were changes from baseline to week 14 in trough, sitting systolic BP, and diastolic BP measured in the clinic. Decreases from baseline to week 14 in systolic BP for darusentan (−15±14 mm Hg) were greater than for guanfacine (−12±13 mm Hg; P
language: eng
source:
identifier: ISSN: 0194-911X
fulltext: no_fulltext
issn:
  • 0194-911X
  • 1524-4563
  • 1524-4563
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6418858
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_swepu
recordidTN_cdi_swepub_primary_oai_DiVA_org_umu_41553
sourceformatXML
sourcesystemPC
sourcerecordid759874961
originalsourceidFETCH-LOGICAL-14203-2a92add5eef8397ccede68a957cba9a1b3a6561c8c84110309e2ddc970dff9bc0
addsrcrecordideNpdkV1v0zAUhi0EYmXwF5CFhLghYMfOh3eXtYVOmrZpdAiuLMc56QxuHOyYqv8eQ8uQsOQPnfO875H8IvSKkneUlvT96uvN8na9vPp0cX3VrJpUTI2iFFX5CM1okfOMFyV7jGaECp4JSr-coGchfCOEcs6rp-gkJyKnnJEZ8gvzE_wGhgnfQoh2CvgumGGD59YMRmM1dLjZttGqyfk9PrfOdfjGQwgxHWdJNDo_YddjhRfKx5Cc1JAlLxPSY8Kr_Qh-giEYN-C1N8o-R096ZQO8ON6n6O7Dcj1fZZfXHy_mzWVGeU5YliuRq64rAPqaiUpr6KCslSgq3SqhaMtUWZRU17rm6QcYEZB3nRYV6fpetJqcorcH37CDMbZy9Gar_F46ZeTCfG6k8xsZt1FyWhQs4W8O-OjdjwhhklsTNFirBnAxyKoQdcVFSRN5diC1dyF46B-sKZG_E5L_JZSKqfEnoSR-eRwT2y10D9K_kSTg9RFQQSvbezVoE_5xjNWVICJx_MDtnJ3Ah-827sDLe1B2upckLZ6XdZYTStJ4QrK0KSO_AL7ZrZM
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid759874961
display
typearticle
titleDivergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial
creatorBakris, George L ; Lindholm, Lars H ; Black, Henry R ; Krum, Henry ; Linas, Stuart ; Linseman, Jennifer V ; Arterburn, Sarah ; Sager, Philip ; Weber, Michael
creatorcontribBakris, George L ; Lindholm, Lars H ; Black, Henry R ; Krum, Henry ; Linas, Stuart ; Linseman, Jennifer V ; Arterburn, Sarah ; Sager, Philip ; Weber, Michael
descriptionPatients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing therapies will help achieve blood pressure (BP) goals in more resistant hypertension patients. In the current trial, 849 patients with resistant hypertension receiving ≥3 antihypertensive drugs, including a diuretic, at optimized doses were randomized to the selective endothelin A receptor antagonist darusentan, placebo, or the central α-2 agonist guanfacine. The coprimary end points of the study were changes from baseline to week 14 in trough, sitting systolic BP, and diastolic BP measured in the clinic. Decreases from baseline to week 14 in systolic BP for darusentan (−15±14 mm Hg) were greater than for guanfacine (−12±13 mm Hg; P<0.05) but not greater than placebo (−14±14 mm Hg). Darusentan, however, reduced mean 24-hour systolic BP (−9±12 mm Hg) more than placebo (−2±12 mm Hg) or guanfacine (−4±12 mm Hg) after 14 weeks of treatment (P<0.001 for each comparison). The most frequent adverse event associated with darusentan was fluid retention/edema at 28% versus 12% in each of the other groups. More patients withdrew because of adverse events on darusentan as compared with placebo or guanfacine. We conclude that darusentan provided greater reduction in systolic BP in resistant hypertension patients as assessed by ambulatory BP monitoring, in spite of not meeting its coprimary end points. The results of this trial highlight the importance of ambulatory BP monitoring in the design of hypertension clinical studies.
identifier
0ISSN: 0194-911X
1ISSN: 1524-4563
2EISSN: 1524-4563
3DOI: 10.1161/HYPERTENSIONAHA.110.156976
4PMID: 20921430
5CODEN: HPRTDN
languageeng
publisherHagerstown, MD: American Heart Association, Inc
subjectAged ; Antihypertensive Agents - therapeutic use ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Pressure - drug effects ; Blood Pressure Monitoring, Ambulatory ; Cardiac and Cardiovascular Systems ; Cardiology. Vascular system ; Clinical manifestations. Epidemiology. Investigative techniques. Etiology ; Clinical Medicine ; endothelin ; endothelin antagonist ; Endothelin Receptor Antagonists ; Female ; Guanfacine - therapeutic use ; Humans ; hypertension ; Hypertension - drug therapy ; Intention to Treat Analysis ; Kardiologi ; Klinisk medicin ; Male ; Medical and Health Sciences ; Medical sciences ; Medicin och hälsovetenskap ; Middle Aged ; Phenylpropionates - therapeutic use ; Pyrimidines - therapeutic use ; resistant hypertension ; Treatment Outcome
ispartofHypertension (Dallas, Tex. 1979), 2010-11, Vol.56 (5), p.824-830
rights
02010 American Heart Association, Inc.
12015 INIST-CNRS
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-14203-2a92add5eef8397ccede68a957cba9a1b3a6561c8c84110309e2ddc970dff9bc0
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23387909$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20921430$$D View this record in MEDLINE/PubMed
2$$Uhttp://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-41553$$DView record from Swedish Publication Index
search
creatorcontrib
0Bakris, George L
1Lindholm, Lars H
2Black, Henry R
3Krum, Henry
4Linas, Stuart
5Linseman, Jennifer V
6Arterburn, Sarah
7Sager, Philip
8Weber, Michael
title
0Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial
1Hypertension (Dallas, Tex. 1979)
addtitleHypertension
descriptionPatients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing therapies will help achieve blood pressure (BP) goals in more resistant hypertension patients. In the current trial, 849 patients with resistant hypertension receiving ≥3 antihypertensive drugs, including a diuretic, at optimized doses were randomized to the selective endothelin A receptor antagonist darusentan, placebo, or the central α-2 agonist guanfacine. The coprimary end points of the study were changes from baseline to week 14 in trough, sitting systolic BP, and diastolic BP measured in the clinic. Decreases from baseline to week 14 in systolic BP for darusentan (−15±14 mm Hg) were greater than for guanfacine (−12±13 mm Hg; P<0.05) but not greater than placebo (−14±14 mm Hg). Darusentan, however, reduced mean 24-hour systolic BP (−9±12 mm Hg) more than placebo (−2±12 mm Hg) or guanfacine (−4±12 mm Hg) after 14 weeks of treatment (P<0.001 for each comparison). The most frequent adverse event associated with darusentan was fluid retention/edema at 28% versus 12% in each of the other groups. More patients withdrew because of adverse events on darusentan as compared with placebo or guanfacine. We conclude that darusentan provided greater reduction in systolic BP in resistant hypertension patients as assessed by ambulatory BP monitoring, in spite of not meeting its coprimary end points. The results of this trial highlight the importance of ambulatory BP monitoring in the design of hypertension clinical studies.
subject
0Aged
1Antihypertensive Agents - therapeutic use
2Arterial hypertension. Arterial hypotension
3Biological and medical sciences
4Blood and lymphatic vessels
5Blood Pressure - drug effects
6Blood Pressure Monitoring, Ambulatory
7Cardiac and Cardiovascular Systems
8Cardiology. Vascular system
9Clinical manifestations. Epidemiology. Investigative techniques. Etiology
10Clinical Medicine
11endothelin
12endothelin antagonist
13Endothelin Receptor Antagonists
14Female
15Guanfacine - therapeutic use
16Humans
17hypertension
18Hypertension - drug therapy
19Intention to Treat Analysis
20Kardiologi
21Klinisk medicin
22Male
23Medical and Health Sciences
24Medical sciences
25Medicin och hälsovetenskap
26Middle Aged
27Phenylpropionates - therapeutic use
28Pyrimidines - therapeutic use
29resistant hypertension
30Treatment Outcome
issn
00194-911X
11524-4563
21524-4563
fulltextfalse
rsrctypearticle
creationdate2010
recordtypearticle
recordideNpdkV1v0zAUhi0EYmXwF5CFhLghYMfOh3eXtYVOmrZpdAiuLMc56QxuHOyYqv8eQ8uQsOQPnfO875H8IvSKkneUlvT96uvN8na9vPp0cX3VrJpUTI2iFFX5CM1okfOMFyV7jGaECp4JSr-coGchfCOEcs6rp-gkJyKnnJEZ8gvzE_wGhgnfQoh2CvgumGGD59YMRmM1dLjZttGqyfk9PrfOdfjGQwgxHWdJNDo_YddjhRfKx5Cc1JAlLxPSY8Kr_Qh-giEYN-C1N8o-R096ZQO8ON6n6O7Dcj1fZZfXHy_mzWVGeU5YliuRq64rAPqaiUpr6KCslSgq3SqhaMtUWZRU17rm6QcYEZB3nRYV6fpetJqcorcH37CDMbZy9Gar_F46ZeTCfG6k8xsZt1FyWhQs4W8O-OjdjwhhklsTNFirBnAxyKoQdcVFSRN5diC1dyF46B-sKZG_E5L_JZSKqfEnoSR-eRwT2y10D9K_kSTg9RFQQSvbezVoE_5xjNWVICJx_MDtnJ3Ah-827sDLe1B2upckLZ6XdZYTStJ4QrK0KSO_AL7ZrZM
startdate201011
enddate201011
creator
0Bakris, George L
1Lindholm, Lars H
2Black, Henry R
3Krum, Henry
4Linas, Stuart
5Linseman, Jennifer V
6Arterburn, Sarah
7Sager, Philip
8Weber, Michael
general
0American Heart Association, Inc
1Lippincott Williams & Wilkins
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
97X8
10ADTPV
11AOWAS
sort
creationdate201011
titleDivergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial
authorBakris, George L ; Lindholm, Lars H ; Black, Henry R ; Krum, Henry ; Linas, Stuart ; Linseman, Jennifer V ; Arterburn, Sarah ; Sager, Philip ; Weber, Michael
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-14203-2a92add5eef8397ccede68a957cba9a1b3a6561c8c84110309e2ddc970dff9bc0
rsrctypearticles
prefilterarticles
languageeng
creationdate2010
topic
0Aged
1Antihypertensive Agents - therapeutic use
2Arterial hypertension. Arterial hypotension
3Biological and medical sciences
4Blood and lymphatic vessels
5Blood Pressure - drug effects
6Blood Pressure Monitoring, Ambulatory
7Cardiac and Cardiovascular Systems
8Cardiology. Vascular system
9Clinical manifestations. Epidemiology. Investigative techniques. Etiology
10Clinical Medicine
11endothelin
12endothelin antagonist
13Endothelin Receptor Antagonists
14Female
15Guanfacine - therapeutic use
16Humans
17hypertension
18Hypertension - drug therapy
19Intention to Treat Analysis
20Kardiologi
21Klinisk medicin
22Male
23Medical and Health Sciences
24Medical sciences
25Medicin och hälsovetenskap
26Middle Aged
27Phenylpropionates - therapeutic use
28Pyrimidines - therapeutic use
29resistant hypertension
30Treatment Outcome
toplevelpeer_reviewed
creatorcontrib
0Bakris, George L
1Lindholm, Lars H
2Black, Henry R
3Krum, Henry
4Linas, Stuart
5Linseman, Jennifer V
6Arterburn, Sarah
7Sager, Philip
8Weber, Michael
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8MEDLINE - Academic
9SwePub
10SwePub Articles
jtitleHypertension (Dallas, Tex. 1979)
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Bakris, George L
1Lindholm, Lars H
2Black, Henry R
3Krum, Henry
4Linas, Stuart
5Linseman, Jennifer V
6Arterburn, Sarah
7Sager, Philip
8Weber, Michael
formatjournal
genrearticle
ristypeJOUR
atitleDivergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial
jtitleHypertension (Dallas, Tex. 1979)
addtitleHypertension
date2010-11
risdate2010
volume56
issue5
spage824
epage830
pages824-830
issn
00194-911X
11524-4563
eissn1524-4563
codenHPRTDN
abstractPatients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing therapies will help achieve blood pressure (BP) goals in more resistant hypertension patients. In the current trial, 849 patients with resistant hypertension receiving ≥3 antihypertensive drugs, including a diuretic, at optimized doses were randomized to the selective endothelin A receptor antagonist darusentan, placebo, or the central α-2 agonist guanfacine. The coprimary end points of the study were changes from baseline to week 14 in trough, sitting systolic BP, and diastolic BP measured in the clinic. Decreases from baseline to week 14 in systolic BP for darusentan (−15±14 mm Hg) were greater than for guanfacine (−12±13 mm Hg; P<0.05) but not greater than placebo (−14±14 mm Hg). Darusentan, however, reduced mean 24-hour systolic BP (−9±12 mm Hg) more than placebo (−2±12 mm Hg) or guanfacine (−4±12 mm Hg) after 14 weeks of treatment (P<0.001 for each comparison). The most frequent adverse event associated with darusentan was fluid retention/edema at 28% versus 12% in each of the other groups. More patients withdrew because of adverse events on darusentan as compared with placebo or guanfacine. We conclude that darusentan provided greater reduction in systolic BP in resistant hypertension patients as assessed by ambulatory BP monitoring, in spite of not meeting its coprimary end points. The results of this trial highlight the importance of ambulatory BP monitoring in the design of hypertension clinical studies.
copHagerstown, MD
pubAmerican Heart Association, Inc
pmid20921430
doi10.1161/HYPERTENSIONAHA.110.156976
oafree_for_read